Document is current
Any future updates will be listed below
-
Authors
Ali, Zaheer
Vildevall, Malin
Rodriguez, Gabriela Vazquez
Tandiono, Decky
Vamvakaris, Ioannis
Evangelou, Georgios
Lolas, Georgios
Syrigos, Konstantinos N.
Villanueva, Alberto
Wick, Michael
Omar, Shenga
Erkstam, Anna
Schueler, Julia
Fahlgren, Anna
Jensen, Lasse D. https://orcid.org/0000-0003-2338-357X
-
Funding
Funding for this research was provided by:
bioreperia ab
h2020 marie skłodowska-curie actions (3D-NEONET)
Linköping University
- License Information
-
More Information
Article History
Received: 30 July 2021
Accepted: 31 January 2022
First Online: 9 February 2022
Declarations
:
: All patients provided informed consent to participate in this study. More details are provided in the materials and methods section.
: All authors consent to this publication.
: AF and LJ own shares in BioReperia AB, where LJ is a board-member. AV is the co-founder and a main shareholder in Xenopat. AZ, MV, GVR, DT and AE are employed at BioReperia AB, JS is employed at Charles River Laboratories. MW is employed as the CSO of XenoSTART. The study was mainly funded by BioReperia AB.
